Request Demo
Recent blog posts
Latest Hotspot
8 min read
NCT07644377 Riociguat Chronic thromboembolic pulmonary hypertension Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07644377 clinical trial report covering Riociguat, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
CTR20262251 UBT-251 Obesity Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
CTR20262251 clinical trial report covering UBT-251, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
CTR20262257 Viable Lactobacillus Quadruple (Sichuan Yanyang Biotechnology) Bacterial Vaginosis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
CTR20262257 clinical trial report covering Viable Lactobacillus Quadruple (Sichuan Yanyang Biotechnology), Phase 3, endpoints, sponsor, geography, readout
Latest Hotspot
8 min read
NCT07647510 Claseprubart Myasthenia Gravis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07647510 clinical trial report covering Claseprubart, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07717411 Trontinemab Alzheimer Disease Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07717411 clinical trial report covering Trontinemab, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
CTR20262350 Herpes zoster mRNA vaccine(Suzhou Abogen) Herpes Zoster Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
CTR20262350 clinical trial report covering Herpes zoster mRNA vaccine(Suzhou Abogen), Phase 3, endpoints, sponsor, geography, readout timing and developmen
Latest Hotspot
8 min read
NCT07647328 Camizestrant ER-positive/HER2-negative Breast Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07647328 clinical trial report covering Camizestrant, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
S1PR1 Biologics Sequence Review Report 2026: Sphingosine 1-phosphate receptor 1 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of S1PR1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
PDGFD Biologics Sequence Review Report 2026: Platelet-derived growth factor D Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of PDGFD protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
PDGFC Biologics Sequence Review Report 2026: Platelet-derived growth factor C Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of PDGFC protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
PDGFB Biologics Sequence Review Report 2026: Platelet-derived growth factor subunit B Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of PDGFB protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
PDGFA Biologics Sequence Review Report 2026: Platelet-derived growth factor subunit A Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of PDGFA protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.